Quick Answer
Quince Therapeutics, Inc. reported Research And Development Expense of $18.59 million for the year ending 2024.
- Quince Therapeutics, Inc. showed an increase of +96.8% in Research And Development Expense from 2023 to 2024.
- This data is from Quince Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2025.
- XBRL data for this metric is available from 2018 to 2024 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $2.41 million | Q2 2018: $2.29 million | Q3 2018: $2.29 million | Q1 2019: $4.83 million | Q2 2019: $7.11 million | Q3 2019: $8.25 million | Q1 2020: $14.38 million | Q2 2020: $14.09 million | Q3 2020: $16.98 million | Q1 2021: $16.82 million | Q2 2021: $14.72 million | Q3 2021: $14.04 million | Q1 2022: $12.76 million | Q2 2022: $7.20 million | Q3 2022: $2.45 million | Q1 2023: $3.23 million | Q2 2023: $1.35 million | Q3 2023: $1.43 million | Q1 2024: $3.70 million | Q2 2024: $4.15 million | Q3 2024: $4.92 million | Q1 2025: $8.15 million | Q2 2025: $6.55 million | Q3 2025: $8.08 million.
- Over the full 7 years of available data (2018 to 2024), Quince Therapeutics, Inc.'s Research And Development Expense has grown by 84.3%.
- Historical annual values: Fiscal year 2024: $18.59 million | Fiscal year 2023: $9.45 million | Fiscal year 2022: $25.18 million | Fiscal year 2021: $60.80 million | Fiscal year 2020: $61.31 million | Fiscal year 2019: $30.21 million | Fiscal year 2018: $10.09 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: